SOLAR: Phase Ib Dose Expansion of Selumetinib (MEK Inhibitor) and OLAparib (PARP Inhibitor) Combination in Solid Tumors with RAS Pathway Alterations and in PARP Inhibitor-Resistant Ovarian Cancer

被引：4
|
作者：
Westin, Shannon [1 ]
Kurnit, Katherine [2 ]
Fellman, Bryan [1 ]
Bhosale, Priya [1 ]
Hong, David [1 ]
Karp, Daniel [1 ]
Naing, Aung [1 ]
Pant, Shubham [1 ]
Piha-Paul, Sarina [1 ]
Fu, Siqing [1 ]
Rodon, Jordi [1 ]
Yap, Timothy [1 ]
Dumbrava, Ecaterina [1 ]
Sood, Anil [1 ]
Shafer, Aaron [1 ]
Soliman, Pamela [1 ]
Gershenson, David [1 ]
Kabil, Nashwa [3 ]
Coleman, Robert [4 ]
Mills, Gordon [5 ]
Meric-Bernstam, Funda [1 ]
机构：
[1] UT MD Anderson Canc Ctr Houston, Houston, TX USA
[2] Univ Chicago, Coll Med, Chicago, IL USA
[3] AstraZeneca, Gaithersburg, MD USA
[4] US Oncol Res, The Woodlands, TX USA
[5] OHSU, Portland, OR USA
来源：
GYNECOLOGIC ONCOLOGY | 2023年 / 176卷
关键词：
D O I：
10.1016/j.ygyno.2023.06.511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA 9
引用
下载
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [21] A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
    Pacey, S.
    Blackhall, F.
    Garcia-Corbacho, J.
    Lipplaa, A.
    Fusi, A.
    Kumar, S.
    Hategan, M.
    Derham, J.
    Laviste, G.
    Halford, S.
    Foxton, C.
    McLeod, R.
    Wan, S.
    Talbot, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib (V) in combination with the oral MEK inhibitor selumetinib (S) in solid tumors.
    Saka, Wasiru Olugbenga
    Pacey, Simon
    Blackhall, Fiona Helen
    Garcia-Corbacho, Javier
    Fusi, Alberto
    Karydis, Ioannis
    Hategan, Mirela
    Laviste, Glenda
    Halford, Sarah E. R.
    Foxton, Caroline
    McLeod, Robert
    Wan, Susan
    Talbot, Denis Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Phase Ⅰ dose-escalation and expansion study of PARP inhibitor,fluzoparib(SHR3162), in patients with advanced solid tumors
    Huiping Li
    Rongrui Liu
    Bin Shao
    Ran Ran
    Guohong Song
    Ke Wang
    Yehui Shi
    Jihong Liu
    Wenjing Hu
    Fu Chen
    Xiaoran Liu
    Gairong Zhang
    Chuanhua Zhao
    Ru Jia
    Quanren Wang
    Hope S.Rugo
    Yifan Zhang
    Guangze Li
    Jianming Xu
    Chinese Journal of Cancer Research, 2020, 32 (03) : 370 - 384
  • [24] Preclinical Evaluation of the PARP Inhibitor, Olaparib, in Combination with Cytotoxic Chemotherapy in Pediatric Solid Tumors (vol 61, pg 145, 2014)
    Norris, R. E.
    Adamson, P. C.
    Nguyen, V. T.
    Fox, E.
    PEDIATRIC BLOOD & CANCER, 2021, 68 (09)
  • [25] A PHASE 1 TRIAL OF THE PARP INHIBITOR VELIPARIB IN COMBINATION WITH INTRAPERITONEAL FLOXURIDINE (FUDR) IN EPITHELIAL OVARIAN CANCER
    Hendrickson, A. Wahner
    Powell, M.
    Mutch, D.
    Tanner, E.
    Cliby, W.
    Swisher, E.
    Ralya, A.
    Reid, J.
    Burton, J.
    Wagner, J.
    Strand, C.
    Allred, J.
    Haluska, P.
    Erlichman, C.
    Ivy, S. P.
    Kaufmann, S.
    Karnitz, L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 460 - 461
  • [26] Phase I study to determine the bioavailability and tolerability of a tablet formulation of the PARP inhibitor olaparib in patients with advanced solid tumors: Dose-escalation phase.
    Gupta, Avinash
    Moreno, Victor
    Dean, Emma Jane
    Drew, Yvette
    Nicum, Shibani
    Ranson, Malcolm
    Plummer, Ruth
    Swaisland, Helen
    Burke, Wendy
    McCormack, Peter
    Tchakov, Ilian
    Middleton, Mark R.
    Kaye, Stanley B.
    Molife, L. Rhoda
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
    Li, Huiping
    Liu, Rongrui
    Shao, Bin
    Ran, Ran
    Song, Guohong
    Wang, Ke
    Shi, Yehui
    Liu, Jihong
    Hu, Wenjing
    Chen, Fu
    Liu, Xiaoran
    Zhang, Gairong
    Zhao, Chuanhua
    Jia, Ru
    Wang, Quanren
    Rugo, Hope S.
    Zhang, Yifan
    Li, Guangze
    Xu, Jianming
    CHINESE JOURNAL OF CANCER RESEARCH, 2020, 32 (03) : 370 - +
  • [28] Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer.
    Westin, Shannon Neville
    Litton, Jennifer Keating
    Williams, Rochelle A.
    Shepherd, Christopher J.
    Brugger, Wolfram
    Pease, Elizabeth J.
    Soliman, Pamela T.
    Frumovitz, Michael M.
    Levenback, Charles F.
    Sood, Anil
    Meyer, Larissa
    Moulder, Stacy L.
    Valero, Vicente
    Saleem, Sadia
    Rodriguez, Anna Marie
    Cyriac, Annies
    Engerman, Laverne
    Samuel, Christine
    Mills, Gordon B.
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors
    Ruth Plummer
    Peter Stephens
    Louiza Aissat-Daudigny
    Anne Cambois
    Gilbert Moachon
    Peter D. Brown
    Mario Campone
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 257 - 265
  • [30] Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors
    Plummer, Ruth
    Stephens, Peter
    Aissat-Daudigny, Louiza
    Cambois, Anne
    Moachon, Gilbert
    Brown, Peter D.
    Campone, Mario
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 257 - 265
12345